Shakti Sahi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shakti Sahi has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
Aman Chandra Kaushik
Department of Bioinformatics and Biological Statistics, School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China
13 shared publicationsAjay Kumar
National Sun Yat-Sen University, Taiwan
11 shared publications- Aman Chandra Kaushik
Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China
11 shared publications - Shiv Bharadwaj
Laboratory of Ligand Engineering, Institute of Biotechnology of the Czech Academy of Sciences BIOCEV Research Center Vestec Czech Republic
11 shared publications Ravi Chaudhary
Gautam Buddha University
8 shared publications- Dong-Qing Wei
School of Life Sciences and Biotechnology, Shanghai Jiao Tong University, Shanghai, China
5 shared publications
Latest Publications
- 19 January 2026
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 76 (1) , 11
Decoding Non-Neuronal Mechanisms and Therapeutic Targets in Huntington’s Disease Through Integrative Transcriptomics and Machine Learning
Huntington’s disease (HD) is a rare, inherited neurodegenerative disorder caused by the expanded CAG repeats in the huntingtin gene. The HD domain still lacks detailed knowledge of validated drug targets, limiting the effectiveness of classical methods. To address this gap, we have applied an integrated computational approach, combining machine learning (ML) with transcriptomic analysis, to identify novel therapeutic targets. Differential expression analysis was performed on eight publicly available datasets, comprising 209 healthy control and 193 Huntington’s disease patient samples, followed by ML-based screening of differentially expressed genes (DEGs). Feature selection using mRMR and RFE, in combination with four classifiers (Linear SVC, Stochastic Gradient Descent, Logistic regression, and Ridge regression), yielded 138 DEG candidates. Subsequent literature curation, drug target analysis, and gene regulatory network (GRN) construction highlighted several key genes, including TXNIP, TNIP3, HTR1D, ADRB1, and FOXP1, which may play pivotal roles in disease progression. Furthermore, our findings highlight the contribution of non-neuronal mechanisms, such as endothelial dysfunction, vascular neurodegeneration, thermoregulation, metabolic imbalance, and impaired phagocytosis, providing a broader perspective into HD pathophysiology. This comprehensive strategy advances our HD knowledge regarding therapeutic targets, molecular pathways, transcription factors (TFs), and complex gene interactions beyond classical HD processes. In summary, the study successfully identifies a promising set of novel drug targets, indicating potential implications in HD therapy.
- 19 January 2026
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 76 (1) , 11
Decoding Non-Neuronal Mechanisms and Therapeutic Targets in Huntington’s Disease Through Integrative Transcriptomics and Machine Learning
Huntington’s disease (HD) is a rare, inherited neurodegenerative disorder caused by the expanded CAG repeats in the huntingtin gene. The HD domain still lacks detailed knowledge of validated drug targets, limiting the effectiveness of classical methods. To address this gap, we have applied an integrated computational approach, combining machine learning (ML) with transcriptomic analysis, to identify novel therapeutic targets. Differential expression analysis was performed on eight publicly available datasets, comprising 209 healthy control and 193 Huntington’s disease patient samples, followed by ML-based screening of differentially expressed genes (DEGs). Feature selection using mRMR and RFE, in combination with four classifiers (Linear SVC, Stochastic Gradient Descent, Logistic regression, and Ridge regression), yielded 138 DEG candidates. Subsequent literature curation, drug target analysis, and gene regulatory network (GRN) construction highlighted several key genes, including TXNIP, TNIP3, HTR1D, ADRB1, and FOXP1, which may play pivotal roles in disease progression. Furthermore, our findings highlight the contribution of non-neuronal mechanisms, such as endothelial dysfunction, vascular neurodegeneration, thermoregulation, metabolic imbalance, and impaired phagocytosis, providing a broader perspective into HD pathophysiology. This comprehensive strategy advances our HD knowledge regarding therapeutic targets, molecular pathways, transcription factors (TFs), and complex gene interactions beyond classical HD processes. In summary, the study successfully identifies a promising set of novel drug targets, indicating potential implications in HD therapy.
- 21 August 2025
- Published by Elsevier in Computational Biology and Chemistry
- Vol. 120 (Pt 1) , 108646
Unveiling therapeutic potential: In Silico discovery of prognostic markers and potential inhibitors for TGFßR1 in pancreatic cancer
- 21 August 2025
- Published by Elsevier in Computational Biology and Chemistry
- Vol. 120 (Pt 1) , 108646
Unveiling therapeutic potential: In Silico discovery of prognostic markers and potential inhibitors for TGFßR1 in pancreatic cancer
- 1 December 2024
- Published by Bentham Science Publishers Ltd. in Current Computer-Aided Drug Design
- Vol. 20 (6) , 955-973
Identification of Prognostic Markers and Potential Therapeutic Targets using Gene Expression Profiling and Simulation Studies in Pancreatic Cancer
Background: Pancreatic ductal adenocarcinoma (PDAC) has a 5-year relative survival rate of less than 10% making it one of the most fatal cancers. A lack of early measures of prognosis, challenges in molecular targeted therapy, ineffective adjuvant chemotherapy, and strong resistance to chemotherapy cumulatively make pancreatic cancer challenging to manage Objective: The present study aims to enhance understanding of the disease mechanism and its progression by identifying prognostic biomarkers, potential drug targets, and candidate drugs that can be used for therapy in pancreatic cancer. Methods: Gene expression profiles from the GEO database were analyzed to identify reliable prognostic markers and potential drug targets. The disease's molecular mechanism and biological pathways were studied by investigating gene ontologies, KEGG pathways, and survival analysis to understand the strong prognostic power of key DEGs. FDA-approved anti-cancer drugs were screened through cell line databases, and docking studies were performed to identify drugs with high affinity for ARNTL2 and PIK3C2A. Molecular dynamic simulations of drug targets ARNTL2 and PIK3C2A in their native state and complex with nilotinib were carried out for 100 ns to validate their therapeutic potential in PDAC. Results: Differentially expressed genes that are crucial regulators, including SUN1, PSMG3, PIK3C2A, SCRN1, and TRIAP1, were identified. Nilotinib as a candidate drug was screened using sensitivity analysis on CCLE and GDSC pancreatic cancer cell lines. Molecular dynamics simulations revealed the underlying mechanism of the binding of nilotinib with ARNTL2 and PIK3C2A and the dynamic perturbations. It validated nilotinib as a promising drug for pancreatic cancer. Conclusion: This study accounts for prognostic markers, drug targets, and repurposed anti-cancer drugs to highlight their usefulness for translational research on developing novel therapies. Our results revealed potential and prospective clinical applications in drug targets ARNTL2, EGFR, and PI3KC2A for pancreatic cancer therapy.
- 1 December 2024
- Published by Bentham Science Publishers Ltd. in Current Computer-Aided Drug Design
- Vol. 20 (6) , 955-973
Identification of Prognostic Markers and Potential Therapeutic Targets using Gene Expression Profiling and Simulation Studies in Pancreatic Cancer
Background: Pancreatic ductal adenocarcinoma (PDAC) has a 5-year relative survival rate of less than 10% making it one of the most fatal cancers. A lack of early measures of prognosis, challenges in molecular targeted therapy, ineffective adjuvant chemotherapy, and strong resistance to chemotherapy cumulatively make pancreatic cancer challenging to manage Objective: The present study aims to enhance understanding of the disease mechanism and its progression by identifying prognostic biomarkers, potential drug targets, and candidate drugs that can be used for therapy in pancreatic cancer. Methods: Gene expression profiles from the GEO database were analyzed to identify reliable prognostic markers and potential drug targets. The disease's molecular mechanism and biological pathways were studied by investigating gene ontologies, KEGG pathways, and survival analysis to understand the strong prognostic power of key DEGs. FDA-approved anti-cancer drugs were screened through cell line databases, and docking studies were performed to identify drugs with high affinity for ARNTL2 and PIK3C2A. Molecular dynamic simulations of drug targets ARNTL2 and PIK3C2A in their native state and complex with nilotinib were carried out for 100 ns to validate their therapeutic potential in PDAC. Results: Differentially expressed genes that are crucial regulators, including SUN1, PSMG3, PIK3C2A, SCRN1, and TRIAP1, were identified. Nilotinib as a candidate drug was screened using sensitivity analysis on CCLE and GDSC pancreatic cancer cell lines. Molecular dynamics simulations revealed the underlying mechanism of the binding of nilotinib with ARNTL2 and PIK3C2A and the dynamic perturbations. It validated nilotinib as a promising drug for pancreatic cancer. Conclusion: This study accounts for prognostic markers, drug targets, and repurposed anti-cancer drugs to highlight their usefulness for translational research on developing novel therapies. Our results revealed potential and prospective clinical applications in drug targets ARNTL2, EGFR, and PI3KC2A for pancreatic cancer therapy.
- 30 October 2024
- Published by Elsevier in Computational Biology and Chemistry
- Vol. 113, 108262
AI screening and molecular dynamic simulation-driven identification of novel inhibitors of TGFßR1 for pancreatic cancer therapy
- 30 October 2024
- Published by Elsevier in Computational Biology and Chemistry
- Vol. 113, 108262
AI screening and molecular dynamic simulation-driven identification of novel inhibitors of TGFßR1 for pancreatic cancer therapy
- Open Access
- 30 May 2024
- Published by International Journal of Pharmaceutical Sciences and Drug Research in International Journal of Pharmaceutical Sciences and Drug Research
- p. 412-425
Deciphering FFAR4 Mediated Functional Pathways and Potential Drug Targets in Diabetes Mellitus: An Integrated Protein Interaction Network Analysis and Kinetic Simulation
Type 2 Diabetes is a metabolic disorder that affects people worldwide. The G-protein coupled receptor (GPCR) known as free fatty acid receptor 4 (FFAR4) has been shown to be a potential therapeutic target for type 2 diabetes mellitus (T2DM)and complications linked to obesity. The present study focuses on the pharmaceutical role of FFAR4 and its potential agonists by predicting anti-diabetic responses, including insulin secretion, glucose uptake and calcium ion concentration levels. We identified differentially expressed genes and elucidated their role extensively through analysis of pathways, molecular mechanisms and linked biological processes. In the present study, a systems biology approach was implemented to establish an interaction network between FFAR4 and its driver’s such as CASR and NR1H4, that highlighted their significance as potential prognostic and therapeutic targets. A mathematical model incorporating biological events mediated by these proteins is studied and simulated using kinetics law reactions. Furthermore, the kinetic simulations were conducted to assess the impact of drug molecules, namely comp35, comp50, compN1 and compN2, on FFAR4 function. The findings reveal FFAR4’s potential as a therapeutic target for the treatment of type 2 diabetes mellitus.
- 30 May 2024
- Published by International Journal of Pharmaceutical Sciences and Drug Research in International Journal of Pharmaceutical Sciences and Drug Research
- p. 412-425
Open AccessDeciphering FFAR4 Mediated Functional Pathways and Potential Drug Targets in Diabetes Mellitus: An Integrated Protein Interaction Network Analysis and Kinetic Simulation
Type 2 Diabetes is a metabolic disorder that affects people worldwide. The G-protein coupled receptor (GPCR) known as free fatty acid receptor 4 (FFAR4) has been shown to be a potential therapeutic target for type 2 diabetes mellitus (T2DM)and complications linked to obesity. The present study focuses on the pharmaceutical role of FFAR4 and its potential agonists by predicting anti-diabetic responses, including insulin secretion, glucose uptake and calcium ion concentration levels. We identified differentially expressed genes and elucidated their role extensively through analysis of pathways, molecular mechanisms and linked biological processes. In the present study, a systems biology approach was implemented to establish an interaction network between FFAR4 and its driver’s such as CASR and NR1H4, that highlighted their significance as potential prognostic and therapeutic targets. A mathematical model incorporating biological events mediated by these proteins is studied and simulated using kinetics law reactions. Furthermore, the kinetic simulations were conducted to assess the impact of drug molecules, namely comp35, comp50, compN1 and compN2, on FFAR4 function. The findings reveal FFAR4’s potential as a therapeutic target for the treatment of type 2 diabetes mellitus.
- 1 December 2023
- Published by Springer Nature in Molecular Diversity
- Vol. 28 (5) , 3331-3347
High-throughput virtual screening of potential inhibitors of GPR52 using docking and biased sampling method for Huntington’s disease therapy
Huntington’s disease (HD) is a rare and progressive neurodegenerative disorder caused by polyglutamine (poly-Q) mutations of the huntingtin (HTT) gene resulting in chorea, cognitive, and psychiatric dysfunctions. Being a monogenic condition, reducing the levels of the mutated huntingtin protein (mHTT) holds promise as an effective therapeutic approach. GPR52, an orphan G-protein coupled receptor (GPCR), enriched in the striatum, is a novel target for slowing down the progression of HD by lowering the mHTT levels. Therefore, the study focuses on identifying potent small-molecule inhibitors for GPR52 using a combination of robust high-throughput virtual screening (HTVS) and pharmacokinetics profiling followed by fast pulling of ligand (FPL) and umbrella sampling (US) simulations. Initially, screening a library of 2,36,545 compounds was done against the binding pocket of GPR52. Based on binding affinity, stereochemical and non-bonded interactions, and pharmacokinetic profiling, 50 compounds were shortlisted. Selected hit compounds 1, 2, and 3 were subjected to FPL simulations with applied external bias potential to investigate their unique dissociation pathways and intermolecular interactions over time. Subsequently, the US simulations were performed on the selected hit compounds to estimate their binding free energy (ΔG). The analysis of the trajectories obtained from simulations revealed that the residues TYR34, TYR185, GLY187, ASP188, ILE189, SER299, PHE300, and THR303 within the active site of GPR52 were significant for efficient ligand binding through the formation of various hydrogen bond interactions and hydrophobic contacts. Out of the three hit compounds, compound 3 had the lowest ΔG of − 20.82 ± 0.44 kcal/mol. The study identified compounds 1, 2, and 3 as potential molecules that can be developed as GPR52 inhibitors holding promise for lowering mHTT levels.
- 1 December 2023
- Published by Springer Nature in Molecular Diversity
- Vol. 28 (5) , 3331-3347
High-throughput virtual screening of potential inhibitors of GPR52 using docking and biased sampling method for Huntington’s disease therapy
Huntington’s disease (HD) is a rare and progressive neurodegenerative disorder caused by polyglutamine (poly-Q) mutations of the huntingtin (HTT) gene resulting in chorea, cognitive, and psychiatric dysfunctions. Being a monogenic condition, reducing the levels of the mutated huntingtin protein (mHTT) holds promise as an effective therapeutic approach. GPR52, an orphan G-protein coupled receptor (GPCR), enriched in the striatum, is a novel target for slowing down the progression of HD by lowering the mHTT levels. Therefore, the study focuses on identifying potent small-molecule inhibitors for GPR52 using a combination of robust high-throughput virtual screening (HTVS) and pharmacokinetics profiling followed by fast pulling of ligand (FPL) and umbrella sampling (US) simulations. Initially, screening a library of 2,36,545 compounds was done against the binding pocket of GPR52. Based on binding affinity, stereochemical and non-bonded interactions, and pharmacokinetic profiling, 50 compounds were shortlisted. Selected hit compounds 1, 2, and 3 were subjected to FPL simulations with applied external bias potential to investigate their unique dissociation pathways and intermolecular interactions over time. Subsequently, the US simulations were performed on the selected hit compounds to estimate their binding free energy (ΔG). The analysis of the trajectories obtained from simulations revealed that the residues TYR34, TYR185, GLY187, ASP188, ILE189, SER299, PHE300, and THR303 within the active site of GPR52 were significant for efficient ligand binding through the formation of various hydrogen bond interactions and hydrophobic contacts. Out of the three hit compounds, compound 3 had the lowest ΔG of − 20.82 ± 0.44 kcal/mol. The study identified compounds 1, 2, and 3 as potential molecules that can be developed as GPR52 inhibitors holding promise for lowering mHTT levels.
- Open Access
- 8 September 2023
- Published by Royal Society of Chemistry (RSC)
- p. P001-P006
Frontmatter
Cheminformatics and Bioinformatics at the Interface with Systems BiologyBridging Chemistry and Medicine Theoretical and Computational Chemistry Series Editor-in
- 8 September 2023
- Published by Royal Society of Chemistry (RSC)
- p. P001-P006
Open AccessFrontmatter
Cheminformatics and Bioinformatics at the Interface with Systems BiologyBridging Chemistry and Medicine Theoretical and Computational Chemistry Series Editor-in
- Open Access
- 1 January 2023
- Published by Current Science Publishing in Journal of Drug Designing and Bioinformatics
- Vol. 1 (2) , 42-57
Detection and diagnosis of pancreatic cancer: Computational biology approaches
- 1 January 2023
- Published by Current Science Publishing in Journal of Drug Designing and Bioinformatics
- Vol. 1 (2) , 42-57
Open AccessDetection and diagnosis of pancreatic cancer: Computational biology approaches
- 25 June 2020
- Published by Bentham Science Publishers Ltd. in Current Computer-Aided Drug Design
- Vol. 16 (3) , 1-15
Novel Toxin-antitoxin System Xn-mazEF from Xenorhabdus nematophi-la: Identification, Characterization and Functional Exploration
Background: Xenorhabdus nematophila maintains species-specific mutual interaction with nematodes of Steinernema genus. Type II Toxin Antitoxin (TA) systems, the mazEF TA system controls stress and programmed cell death in bacteria. Objective: This study elucidates the functional characterization of Xn-mazEF, a mazEF homolog in X. nematophila by computational and in vitro approaches. Methods: 3 D- structural models for Xn-MazE toxin and Xn-MazF antitoxin were generated, validated and characterized for protein - RNA interaction analysis. Further biological and cellular functions of Xn-MazF toxin were also predicted. Molecular dynamics simulations of 50ns for Xn-MazF toxin complexed with nucleic acid units (DU, RU, RC, and RU) were performed. The MazF toxin and complete MazEF operon were endogenously expressed and monitored for the killing of Escherichia coli host cells under arabinose induced tightly regulated system. Results: Upon induction, E. coli expressing toxin showed rapid killing within four hours and attained up to 65% growth inhibition, while the expression of the entire operon did not show significant killing. The observation suggests that the Xn-mazEF TA system control transcriptional regulation in X. nematophila and helps to manage stress or cause toxicity leading to programmed death of cells. Conclusion: The study provides insights into structural and functional features of novel toxin, XnMazF and provides an initial inference on control of X. nematophila growth regulated by TA systems.
- 25 June 2020
- Published by Bentham Science Publishers Ltd. in Current Computer-Aided Drug Design
- Vol. 16 (3) , 1-15
Novel Toxin-antitoxin System Xn-mazEF from Xenorhabdus nematophi-la: Identification, Characterization and Functional Exploration
Background: Xenorhabdus nematophila maintains species-specific mutual interaction with nematodes of Steinernema genus. Type II Toxin Antitoxin (TA) systems, the mazEF TA system controls stress and programmed cell death in bacteria. Objective: This study elucidates the functional characterization of Xn-mazEF, a mazEF homolog in X. nematophila by computational and in vitro approaches. Methods: 3 D- structural models for Xn-MazE toxin and Xn-MazF antitoxin were generated, validated and characterized for protein - RNA interaction analysis. Further biological and cellular functions of Xn-MazF toxin were also predicted. Molecular dynamics simulations of 50ns for Xn-MazF toxin complexed with nucleic acid units (DU, RU, RC, and RU) were performed. The MazF toxin and complete MazEF operon were endogenously expressed and monitored for the killing of Escherichia coli host cells under arabinose induced tightly regulated system. Results: Upon induction, E. coli expressing toxin showed rapid killing within four hours and attained up to 65% growth inhibition, while the expression of the entire operon did not show significant killing. The observation suggests that the Xn-mazEF TA system control transcriptional regulation in X. nematophila and helps to manage stress or cause toxicity leading to programmed death of cells. Conclusion: The study provides insights into structural and functional features of novel toxin, XnMazF and provides an initial inference on control of X. nematophila growth regulated by TA systems.
- 7 December 2019
- Published by Springer Nature in Interdisciplinary Sciences: Computational Life Sciences
- Vol. 12 (2) , 169-177
CytoMegaloVirus Infection Database: A Public Omics Database for Systematic and Comparable Information of CMV
CytoMegaloVirus (CMV) is known to cause infection in humans and may remain dormant throughout the life span of an individual. CMV infection has been reported to be fatal in patients with weak immunity. It is transmitted through blood, saliva, urine, semen and breast milk. Although medications are available to treat the infected patients, there is no cure for CMV. This concern prompted us to construct a comprehensive database having exhaustive information regarding CMV, its infections and therapies to be available on a single platform. Thus, we propose a newly designed database that includes all the information from various public resources such as biological databases, virus taxonomy databanks, viral databases, and drug bank, integrated into this database, named as cytomegalovirus database (CMVdb). It features all the relevant data regarding the strains of CMV, genes, expressed proteins, the genomic sequence of CMV and drugs used in the treatment of cytomegalovirus infection. CMVdb has a unique feature of in-house data analysis, so all the data obtained from various resources are processed within the system. The user interface is more responsive because of the integrated platform that will highly facilitate the researchers. Based on CMVdb functionality and quality of the data, it will accelerate the research and development in the field of infectious diseases and immunology with a special focus on CMV. The obtained data would be useful in designing better therapeutic strategies and agents for the treatment of CMV infections. The proposed database (CMVdb) is freely accessible at http://shaktisahislab.com/include/CMV/ or http://weislab.com/WeiDOCK/include/content/CMV/ .
- 7 December 2019
- Published by Springer Nature in Interdisciplinary Sciences: Computational Life Sciences
- Vol. 12 (2) , 169-177
CytoMegaloVirus Infection Database: A Public Omics Database for Systematic and Comparable Information of CMV
CytoMegaloVirus (CMV) is known to cause infection in humans and may remain dormant throughout the life span of an individual. CMV infection has been reported to be fatal in patients with weak immunity. It is transmitted through blood, saliva, urine, semen and breast milk. Although medications are available to treat the infected patients, there is no cure for CMV. This concern prompted us to construct a comprehensive database having exhaustive information regarding CMV, its infections and therapies to be available on a single platform. Thus, we propose a newly designed database that includes all the information from various public resources such as biological databases, virus taxonomy databanks, viral databases, and drug bank, integrated into this database, named as cytomegalovirus database (CMVdb). It features all the relevant data regarding the strains of CMV, genes, expressed proteins, the genomic sequence of CMV and drugs used in the treatment of cytomegalovirus infection. CMVdb has a unique feature of in-house data analysis, so all the data obtained from various resources are processed within the system. The user interface is more responsive because of the integrated platform that will highly facilitate the researchers. Based on CMVdb functionality and quality of the data, it will accelerate the research and development in the field of infectious diseases and immunology with a special focus on CMV. The obtained data would be useful in designing better therapeutic strategies and agents for the treatment of CMV infections. The proposed database (CMVdb) is freely accessible at http://shaktisahislab.com/include/CMV/ or http://weislab.com/WeiDOCK/include/content/CMV/ .